Intuitive Surgical stock trades at a premium as Q2 2026 growth supports robotic surgery demand
Published on 08/29/2026 at 07:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Intuitive Surgical Inc. (ISIN US46120E6023) stock is trading in the high $360s to low $370s range as of late August 2026, reflecting a market view that the company’s Q2 2026 growth and cash generation justify a substantial valuation multiple.
Per recent market data snapshots dated August 28, 2026, one intraday quote shows Intuitive Surgical stock at $370.11 on its Nasdaq listing, 1.21% above a prior close of $367.07, while another quote cites $367.33 alongside a market capitalization of $133.2 billion and trading volume near 949,300 shares. Ad-hoc-news coverage of Intuitive Surgical market data
A separate same-day overview notes that Intuitive Surgical shares closed a recent session at $372.60, up 1.51%, underscoring that investors are still willing to pay a premium for the company’s position in robotic surgery despite a volatile broader market backdrop. Yahoo Finance article on Intuitive Surgical stock performance
Q2 2026 growth and cash flow profile
Recent analysis of Intuitive Surgical’s financial performance highlights that the company’s latest reported quarter, Q2 2026, delivered solid expansion in key metrics including revenue, procedure volumes and free cash flow, forming the core of today’s valuation narrative.
One detailed breakdown emphasizes that Intuitive Surgical generated record free cash flow in the most recently reported period and has been using that cash to accelerate upgrades to its robotic surgery platforms rather than simply returning capital, a deployment choice that underlines management’s confidence in the long-term demand trajectory. Simply Wall St analysis of Intuitive Surgical free cash flow and platform investment
While specific Q2 2026 revenue and earnings-per-share figures are not enumerated in these summaries, the commentary repeatedly ties record free cash flow directly to current upgrade programs for the da Vinci surgical system, implying that cash generation is strong enough to fund both platform investment and ongoing operational needs within the quarter’s reporting window.
Investors can therefore anchor their view of Intuitive Surgical stock not only in the $133.2 billion market cap cited as of August 28, 2026, but also in the qualitative confirmation that the most recent quarter produced record cash inflows that are being reinvested into next-generation robotics.
Valuation context and performance comparison
For many retail investors, a central question is how Intuitive Surgical’s current share-price level and valuation compare with recent history and broader robotics-focused investments.
An Argentine market overview of robotics-linked instruments points out that Intuitive Surgical’s Cedear, which represents exposure to the company’s Nasdaq-listed shares under the ISRG code, has been under pressure in 2026 even as demand for surgical robotics expands. El Cronista article on robotics-linked Cedears including Intuitive Surgical
That same overview notes that as of August 27, 2026, Intuitive Surgical’s share price had fallen approximately 35 percent in dollar terms during 2026 after pulling back from its annual high, even though the underlying business remains described as a consolidated, non-experimental operation in the health care sector.
The contrast is striking for investors: as of late August 2026 the company commands a market capitalization of $133.2 billion alongside recent prices near $370 per share, yet the year-to-date performance still reflects a decline near 35 percent from levels seen earlier in 2026, suggesting that the stock remains below its peak while fundamentals and cash generation continue to support a rich multiple.
One Indian-facing investment portal additionally highlights a medium-term target price of $478.01 for Intuitive Surgical, representing an indicated upside of 22 percent relative to a cited current price of $372.86 as of August 29, 2026 at 1:05 a.m. IST, reinforcing the view that some market participants expect the shares to recover toward prior highs. INDmoney live share price and target overview for Intuitive Surgical
From a quantitative perspective, these figures collectively show Intuitive Surgical stock trading around $370 per share as of August 28-29, 2026, with analysts and market data providers citing a potential path toward the upper $470s, a spread that encapsulates both the recent 35 percent year-to-date decline and an anticipated medium-term recovery.
Da Vinci 5 and procedure growth
The investment story for Intuitive Surgical is inseparable from the adoption curve of its flagship product line, the da Vinci robotic surgery systems, and recent hospital-level developments provide tangible evidence of ongoing demand.
A regional report from the United States notes that doctors at a major medical center performed 1,200 robotic surgeries last year and expect to perform 1,600 robotic surgeries this year thanks to the addition of the new da Vinci 5 model, underscoring that real-world procedure volumes are increasing as next-generation systems roll out. Regional news report on addition of da Vinci 5 surgical robot
The step up from 1,200 to 1,600 robotic surgeries represents growth of 33.3 percent in expected procedure count at that facility alone between last year and this year, highlighting how new installations can materially expand utilization once surgeons and patients adjust to minimally invasive workflows.
Separate clinical coverage from Asia describes minimally invasive single-incision procedures using da Vinci technology in complex areas such as breast cancer surgery, where advantages include limited tissue damage, low blood loss and faster postoperative recovery, and notes that such robotic techniques are already widely applied in prostate cancer, kidney and ureter reconstruction, uterine fibroid removal, oral cancer and other specialties. FTV News coverage of minimally invasive da Vinci-assisted breast surgery
For investors in Intuitive Surgical stock, these procedure and application examples matter because they translate the company’s platform investments and record free cash flow into real-world utilization, reinforcing the thesis that growth in minimally invasive procedures should support recurring instrument and service revenue over time.
Da Vinci surgical system as flagship product
Intuitive Surgical’s core commercial offering is the da Vinci surgical system, a robotic-assisted platform that enables surgeons to perform minimally invasive operations with enhanced precision and control compared with traditional open techniques.
The company’s own information hubs and communities describe da Vinci procedures as involving specialized instruments and camera systems inserted through small incisions, with the surgeon operating from a console that translates hand movements into fine instrument actions inside the body, while acknowledging that serious or life-threatening complications remain possible and that da Vinci surgery does not eliminate the risks inherent in major operations. Da Vinci Surgery online community on gynecologic procedures and risks
Across gynecology, urology, general surgery and emerging areas such as breast surgery, the platform’s value proposition centers on reduced tissue trauma, lower blood loss and shorter hospital stays, which in turn support hospital economics and patient satisfaction and underpin the continued willingness of providers to invest in new models like da Vinci 5.
Shares, valuation and investor view
Intuitive Surgical stock is listed on Nasdaq under the ISRG ticker, and recent quotes as of August 28-29, 2026 cluster between $367 and $373 per share, with a highlighted intraday price of $370.11 as of August 28, 2026 at 2:19 p.m. ET and another data point at $372.86 in early-hours trading on August 29, 2026.
Using the cited market capitalization of $133.2 billion as of August 28, 2026 and the share-price levels around $370, investors can infer that the market continues to assign Intuitive Surgical a robust valuation for its leadership position in robotic surgery, even after a year-to-date decline of 35 percent in dollar terms through August 27, 2026.
For retail investors evaluating Intuitive Surgical stock, the current picture combines premium pricing and a rich market cap with record free cash flow deployment into platform upgrades, growing global procedure volumes and an expanding array of minimally invasive indications, all of which are likely to remain central considerations ahead of the company’s next earnings release.
Read more
More on Intuitive Surgical stock and its investor relations materials is available on the company’s official site. Intuitive Surgical investor relations site
Da Vinci robotic surgery platform
Intuitive Surgical’s da Vinci robotic surgery platform is a multi-component system that combines surgeon consoles, patient-side robots and advanced visualization to facilitate minimally invasive procedures across a wide range of specialties.
The platform’s ongoing evolution, including the introduction of models such as da Vinci 5, reflects the company’s strategy of using its record free cash flow to upgrade installed systems and expand procedural capabilities, supporting long-term demand for instruments, accessories and services associated with the system.
Closing view on Intuitive Surgical stock
As of August 28, 2026 at 2:19 p.m. ET, one intraday snapshot showed Intuitive Surgical stock trading at $370.11 on Nasdaq, with a market capitalization of $133.2 billion and trading volume near 949,300 shares, positioning the company among the largest health technology names linked to surgical robotics.
Against the backdrop of a 35 percent year-to-date share-price decline in 2026 as of August 27, 2026 and ongoing growth in robotic procedure volumes, Intuitive Surgical stock continues to represent a high-valuation play on the expansion of minimally invasive surgery worldwide.
Fact box
Company: Intuitive Surgical Inc.
ISIN: US46120E6023
Ticker: ISRG
Exchange: Nasdaq
Price (as of August 28, 2026, 2:19 p.m. ET): $370.11 USD
Market cap: $133.2 billion (as of August 28, 2026)
Sector / Industry: Health care equipment and supplies
Index membership: S&P 500
